Intelligence Feed event · Equity · 2026-09-01

    Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO

    Question

    Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO

    Direct answer

    Disc Medicine disclosed upcoming clinical presentations scheduled for the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston. The portfolio updates include initial Phase 2 RESTORE-PV trial data for DISC-3405 in patients with polycythemia vera. The company will also present efficacy results from the RALLY-MF trial evaluating DISC-0974 in myelofibrosis-associated anemia. The conference presentations will serve as key clinical milestones for Disc Medicine's pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO”, revision 1, evidence through 2026-09-01. https://marketontology.com/market-events/2026-09-01/disc-medicine-to-present-phase-2-restore-pv-and-rally-mf-trial-data-at-soho-36d840

    EQUITY
    Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO
    Disc Medicine disclosed upcoming clinical presentations scheduled for the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston. The portfolio updates include initial Phase 2 RESTORE-PV trial data for DISC-3405 in patients with polycythemia vera. The company will also present efficacy results from the RALLY-MF trial evaluating DISC-0974 in myelofibrosis-associated anemia. The conference presentations will serve as key clinical milestones for Disc Medicine's pipeline.
    IRON
    Impact
    64
    SEP 1
    SIG
    85%
    IRON
    Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO
    Disc Medicine disclosed upcoming clinical presentations scheduled for the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston. The portfolio updates include initial Phase 2 RESTORE-PV trial data for DISC-3405 in patients with polycythemia vera. The company will also present efficacy results from the RALLY-MF trial evaluating DISC-0974 in myelofibrosis-associated anemia. The conference presentations will serve as key clinical milestones for Disc Medicine's pipeline.
    → Positive Phase 2 hematology readouts validate Disc Medicine's clinical pipeline value, driving revisions in DISC-3405 and DISC-0974 commercial peak sales projections.
    Impact
    Disc Medicine disclosed upcoming clinical presentations scheduled for the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston. The portfolio updates include initial Phase 2 RESTORE-PV trial data for DISC-3405 in patients with polycythemia vera. The company will also present efficacy results from the RALLY-MF trial evaluating DISC-0974 in myelofibrosis-associated anemia. The conference presentations will serve as key clinical milestones for Disc Medicine's pipeline.
    Affected
    IRON
    Transmission
    Positive Phase 2 hematology readouts validate Disc Medicine's clinical pipeline value, driving revisions in DISC-3405 and DISC-0974 commercial peak sales projections.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IRONclinical pipeline milestone readoutUp1-5dDisc Medicine presents RESTORE-PV and RALLY-MF Phase 2 trial results at SOHO 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month